KEYNOTE-799: 帕博利珠单抗联合同步放化疗治疗Ⅲ期不可切除NSCLC的Ⅱ期临床研究

    KEYNOTE-799: Pembrolizumab Plus Concurrent Chemoradiation in Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer

    /

    返回文章
    返回